DO FAIR AND JUST SYSTEMS REQUIRE COMPENSATION
FOR THE DISADVANTAGES OF THE NATURAL LOTTERY?
A DISCUSSION ON SOCIETY’S DUTIES ON THE
PROVISION OF GENE THERAPY Ekmekci PE1,*, Güner MD2 *Corresponding Author: Perihan E. Ekmekci, M.D., Ph.D., Department of History of Medicine and Ethics,
TOBB Economics and Technology University Medical School, Sogutozu Cad. No: 43, 06560 Ankara, Turkey.
Tel: +90-532-262-0350. Fax: +90-312-292-4432. E-mail: p.ekmekci@etu.edu.tr; drpelifek@gmail.com page: 69
|
REFERENCES
1. Glybera EPAR summary for public (https://www.
ema.europa.eu/en/medicines/human/EPAR/glybera).
2. Strimvelis EPAR summary for public (https://www.
ema.europa.eu/en/medicines/human/EPAR/strimvelis).
3. Aiuti A, Roncarolo MG, Naldini L. Gene therapy
for ADA-SCID, the first marketing approval of an
ex vivo gene therapy in Europe: Paving the road for
the next generation of advanced therapy medicinal
products. EMBO Mol Med. 2017; 9(6): 737-740.
4. Food and Drug Administration. Approval History,
Letters, Reviews, and Related Documents. IMLYGIC.
2015 (https://www.fda.gov/BiologicsBloodVaccines/
CellularGeneTherapyProducts/ApprovedProducts/
ucm 469411. htm).
5. Food and Drug Administration. Approval History,
Letters, Reviews and Related Documents. KYMRIAH.
2017 (https://www.fda.gov/Biologics Blood
Vaccines/ CellularGeneTherapyProducts/Approved-
Products/ ucm573706.htm).
6. Food and Drug Administration. Approval History,
Letters, Reviews and Related Documents. YESCARTA.
2017 (https://www.fda.gov/BiologicsBloodVaccines/
CellularGeneTherapyProducts/ApprovedProducts/
ucm58122 2. htm).
7. Food and Drug Administration. December 19, 2017
Approval Letter. LUXTURNA. 2017 (https://www.
fda. gov/BiologicsBloodVaccines/CellularGeneTherapyProducts/
ApprovedProducts/ucm589507.htm).
8. Flotte TR. Ethical implications of the cost of molecularly
targeted therapies. Hum Gene Ther. 2015;
26(9): 573-574.
9. Regalado A. The world’s most expensive medicine
is a bust. MIT Technol Rev. 2016 (https://www.
technology review.com/s/601165/the-worlds-mostexpensive-
medicine-is-a-bust/).
10. Rawls JA. Theory of Justice (original ed). Cambridge,
MA, USA: The Belknap Press, 2005; 60-65; 118-142.
11. O’Brian WE Jr. Equality in law and philosophy. Inquiry.
2010; 53(3): 257-284. doi: 10.1080/0020174100
3784648. 12. Buchanan A, Brock DW, Daniels N, Wilker D. From
Chance to Choice. Genetics and Justice. Cambridge,
Cambridgeshire, UK: University Press, 2000.
13. Daniels N. Just Health: Meeting Health Needs Fairly.
New York, NY, USA: Cambridge University Press,
2008.
14. Arneson RJ. Luck egalitarianism interpreted and defended.
Philosophical Topics. 2004; 32(1-2): 1-20.
15. Ekmekci PE, Arda, B. Luck egalitarianism, individual
responsibility and health. Balkan Med J. 2015; 32(3):
244-254.
|
|
|
|
|
Number 26 Number 26 VOL. 26(2), 2023 All in one |
Number 26 VOL. 26(2), 2023 |
Number 26 VOL. 26, 2023 Supplement |
Number 26 VOL. 26(1), 2023 |
Number 25 VOL. 25(2), 2022 |
Number 25 VOL. 25 (1), 2022 |
Number 24 VOL. 24(2), 2021 |
Number 24 VOL. 24(1), 2021 |
Number 23 VOL. 23(2), 2020 |
Number 22 VOL. 22(2), 2019 |
Number 22 VOL. 22(1), 2019 |
Number 22 VOL. 22, 2019 Supplement |
Number 21 VOL. 21(2), 2018 |
Number 21 VOL. 21 (1), 2018 |
Number 21 VOL. 21, 2018 Supplement |
Number 20 VOL. 20 (2), 2017 |
Number 20 VOL. 20 (1), 2017 |
Number 19 VOL. 19 (2), 2016 |
Number 19 VOL. 19 (1), 2016 |
Number 18 VOL. 18 (2), 2015 |
Number 18 VOL. 18 (1), 2015 |
Number 17 VOL. 17 (2), 2014 |
Number 17 VOL. 17 (1), 2014 |
Number 16 VOL. 16 (2), 2013 |
Number 16 VOL. 16 (1), 2013 |
Number 15 VOL. 15 (2), 2012 |
Number 15 VOL. 15, 2012 Supplement |
Number 15 Vol. 15 (1), 2012 |
Number 14 14 - Vol. 14 (2), 2011 |
Number 14 The 9th Balkan Congress of Medical Genetics |
Number 14 14 - Vol. 14 (1), 2011 |
Number 13 Vol. 13 (2), 2010 |
Number 13 Vol.13 (1), 2010 |
Number 12 Vol.12 (2), 2009 |
Number 12 Vol.12 (1), 2009 |
Number 11 Vol.11 (2),2008 |
Number 11 Vol.11 (1),2008 |
Number 10 Vol.10 (2), 2007 |
Number 10 10 (1),2007 |
Number 9 1&2, 2006 |
Number 9 3&4, 2006 |
Number 8 1&2, 2005 |
Number 8 3&4, 2004 |
Number 7 1&2, 2004 |
Number 6 3&4, 2003 |
Number 6 1&2, 2003 |
Number 5 3&4, 2002 |
Number 5 1&2, 2002 |
Number 4 Vol.3 (4), 2000 |
Number 4 Vol.2 (4), 1999 |
Number 4 Vol.1 (4), 1998 |
Number 4 3&4, 2001 |
Number 4 1&2, 2001 |
Number 3 Vol.3 (3), 2000 |
Number 3 Vol.2 (3), 1999 |
Number 3 Vol.1 (3), 1998 |
Number 2 Vol.3(2), 2000 |
Number 2 Vol.1 (2), 1998 |
Number 2 Vol.2 (2), 1999 |
Number 1 Vol.3 (1), 2000 |
Number 1 Vol.2 (1), 1999 |
Number 1 Vol.1 (1), 1998 |
|
|